Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357

Clinical Infectious Diseases(2025)10.1093/cid/ciaf375Source: DataRank Database

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357 is a research paper published in Clinical Infectious Diseases (2025). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 3.98)OA: greenTopics (45)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (51)

Yu Zheng ORCID,Katherine Rodríguez ORCID,Leah Burke ORCID,Jacqueline D. Reeves,Kimberly K. Scarsi ORCID

Live enrichment

PubMed:40663628 OpenAlex:https://openalex.org/W4412432158

National Institutes of Health

Grant: UM1 AI068634

National Institutes of Health

Grant: UM1 AI068636

National Institutes of Health

Grant: UM1 AI106701

National Institutes of Health

Grant: UM1 AI069412

National Institutes of Health

Grant: VRC07-523LS

National Institute of Allergy and Infectious Diseases

Vaccine Research Center

National Institute of Allergy and Infectious Diseases

Vaccine Research Center

FWCI

3.98

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13375560/

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf375/63772058/ciaf375.pdf

publisherhttps://academic.oup.com/cid/article-pdf/82/1/100/63772058/ciaf375.pdf

journalhttps://doi.org/10.1093/cid/ciaf375

Fields of Study

HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and InterventionsHumansMaleFemaleHIV-1AdultHIV InfectionsPyridonesMiddle AgedAnti-HIV AgentsViral LoadTreatment OutcomeCD4 Lymphocyte CountBroadly Neutralizing AntibodiesAdministration, OralDiketopiperazines

MeSH Terms

Broadly Neutralizing AntibodiesAdministration, OralAdultFemaleHumansMaleMiddle AgedPyridonesHIV-1HIV InfectionsTreatment OutcomeCD4 Lymphocyte CountAnti-HIV AgentsViral LoadDiketopiperazines

Keywords

MedicineHuman immunodeficiency virus (HIV)Viral loadClinical trialVirologyPharmacologyInternal medicineVirologic SuppressionBroadly Neutralizing Antibodies (Bnabs)Vrc07-523lsLong-acting ArtCabotegravir (Cab-la)

Sustainable Development Goals

SDG 0: Good health and well-being

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357

FAIR Checklist

Authors (51)

Funding (9 grants)

Impact

Open Access

Topics